In a study0 dealing with the isolation and the identification of compounds present in the mother liquor concentrates from commercial crystallization of erythromycin, a numberof compoundswere obtained. Some of these compounds were identified as erythromycins A, B, C and D, erythromycin A enol ether, anhydroerythromycin A, anhydroerythromycin C and anhydro-A^-demethylerythromycin A. Five other compounds denoted Ml to M5 were not identified. The determination of the structure of the latter group of compounds is the subject of this paper.
Results and Discussion
Three of the compounds were found to be derivatives of ring-contracted or so-called pseudoerythromycin, in which the macrolide ring was contracted by a C13-»Cntrans-lactonization. Two of these compounds, i.e., M3, pseudo-erythromycin A-6,9-hemiketal (3) and M2, 8,9-anhydro-pseudoerythromycin A-6,9-hemiketal (pseudo-erythromycin A enol ether) (4), are directly derived from erythromycin A (1). Details of their synthesis from 1 and of their structural assignment are described elsewhere2).
The third pseudo-erythromycin derivative, M5, was found to be 8,9-anhydro-pseudo-iV-deniethylerythromycin A-6,9-hemiketal (pseudo-A^-demethylerythromycin A enol ether) (5). The structure was established by comparison of its 13C NMRchemical shifts with those of4 (Table 1) , and by chemical transformation. The chemical shifts of the aglycon and cladinosyl carbons of 4 and 5 are essentially the same, and the up field shift of the /3-carbons (C-3' and NCH3) and the down field shift of the ycarbons (C-2' and C-4') are fully in accordance with the absence of one of the iV-methyl groups in the desosamine moiety of 5. This is also confirmed by the^NMRspectrum where the singlet at 8 2.38 Present address: Department of Pharmacy, University of Nairobi, P.O. Box 30197, Nairobi, Kenya.
integrates for only 3H instead of 6H. Compound5 has a molecular ion at m/z 701 and a base peak at m/z 144 indicating that it is an JV-demethylated derivative of 4. Compound4 has a molecular ion m/z 715 and a base peak at m/z 158 (desosaminyl). Compound 5 is readily prepared from iV-demethylerythromycin A by heating a solution of the latter in a 3 : 1 mixture of pyridine -acetic acid at 50°C for 14 days or at 70°C for 1 day. A similar procedure was used for the preparation of 4 from 12).
iV-Methylation of 5 with formaldehyde and cyanoborohydride by the procedure of Borch and Hassid3) gives 4. The structure of the two other compoundsMl and M4was established as 5-0-desosaminylerythronolide A (6) and 15-nor-erythromycin C (7) respectively.
5-6>-Desosaminylerythronolide A (6) gives a mass spectrum with a molecular ion at m/z 575 suggesting the decladinosyl analog of 1. The presence of erythronolide A (aglycone) is inferred from the fragment ion at m/z 3834) and a weak UVabsorption at 285 nm. The presence of desosamine is shown by a fragment ion at m/z 158, and by the characteristic N(CH3)2 signal at 3 2.28 in its XHNMR spectrum. Absence of the neutral sugar is indicated by the lack of typical fragment ions at m/z 127 and 115i:>, and also by the absence of the corresponding absorptions in the XHNMRspectrum (e.g. no OCH3-signal at about 3 3.30) and in the 13C NMRspectrum (Table 1 ). This spectrum also shows a 3 value of 93.2 ppm for C-5 compared to 83.5 ppm for 1 which may be explained by hydrogen bonding of the oxygen at C-5 with the free hydroxyl group on C-3. When 6 (Rf 0.39) was dissolved in 0.75 n hydrochloric acid and kept at room temperature for 20 hours, it was transformed into a compound with Rf 0.33. The compound was isolated by preparative TLC and shown, by UV, IR and MS, to be identical with authentic erythralosamine obtained by acid degradation of 15). As final proof, a sample of 5-Odesosaminylerythronolide A was prepared from 1 according to the procedure of LeMahieu et al.6\ The IR, UV and MSspectra are identical with those obtained for 6.
15-Nor-erythromycin C (7) gives a mass spectrum with a molecular ion at m/z 705 and fragment MIC: Minimuminhibitory concentration. ions at m/z 158 and 145. The latter two fragment ions, together with the 6H-singlet at d 2.29 and the lack of the OCH3-signal at about 3.30 ppm in the *H NMRspectrum, point to desosamine and mycarose respectively, suggesting that the compound corresponds to erythromycin C (2) lacking a methyl group (14 amu) in the aglycon. This is confirmed by the presence ofa fragment ion at m/z 369, being the analog of the ion at m/z 383 in 1 and 2. The presence of a fragment ion at m/z 634, which is also present in the mass spectrum of 2 and which arises from elimination of the C-12~C-15 fragment, indicates the absence of the methyl group in the lost fragment. The structure was further established by comparing the 13C NMRchemical shifts of 2 and 7 ( Table 1 ). The chemical shifts are almost identical except for C-13 of 7 which shows an up field shift of 5.3 ppm indicating the loss of a methyl substituent in a /3-position. It was further observed by off-resonance spin decoupling experiments that the triplet of C-14 in 2 is absent in the spectrum of 7 and is replaced by a quadruplet signal (CH3) at 13.7 ppm (J= -7.3 ppm, a-effect), thus confirming the absence of the C-15 methyl group.
The antibacterial activity of compounds 1 to 7 was determined against various bacteria by the plate dilution method in a Mueller-Hinton mediumcontaining 5% of lysed blood (pH 7.4) ( Table  2 ). The compounds3 to 7 are muchless active than either 1 or even 2.
The presence of pseudo-erythromycin A-6,9-hemiketal (3), pseudo-erythromycin A enol ether (4) and pseudo-7V-demethylerythromycin A enol ether (5) The presence of 5-0-desosaminylerythronolide A (6) does not fit in the biosynthetic scheme proposed for erythromycins4>8). Thus there are two possibilities, first that the compoundis a metabolite of 1 produced by S. erythraeus and second that the biosynthesis of erythromycins may proceed through a pathway involving this compound. The latter possibility is not excluded since it has been demonstrated, contrary to prior held beliefs, that erythronolide A is glycosylated to erythromycin A9). The presence of 15-nor-erythromycin C can be explained as follows: Erythromycin aglycon is formed by condensation of seven propionate units10). One propionate is used as a starter unit, at C-13, C-14 and C-15, to which are condensed six propionates as chain extending unitsn). The biosynthesis of 15-nor-erythromycin C (7) may be easily rationalized within the proposed biosynthetic routes4-8) if an acetate instead of propionate is incorporated as the starter unit. This scheme corresponds to the biosynthesis of oleandomycin. It should be mentioned that 8,8a-deoxyoleandolide has been isolated from a mutant of Streptomyces erythraeus12).
Experimental
General TLC was performed on precoated Silica gel 60 F254 plates (E. Merck) with CH2C12 -MeOH-25 % NH4OH(90:9 : 1.5). Spots were visualized by spraying with 4-methoxybenzaldehyde -H2SO4-EtOH (1 : 1 : 9) followed by heating at 110°C for 1 minute. Melting points were determined in open capillary tubes using a Biichi apparatus. Optical rotations were obtained in MeOHwith a Thorn-NPL automatic polarimeter Type 243 (Thorn Automation, U.K.). IR spectra were recorded with a Perkin-Elmer model 197 spectrophotometer. UVspectra were obtained in MeOHwith a Beckman model 25 spectrophotometer. Mass spectra were obtained on an AEI MS-12mass spectrometer operated at accelerating voltage 8 kV, trap current 100 juA, ionization energy 70 eV and ion source temperature 150~170°C. Samples were introduced with the direct insertion probe. *H NMRspectra (90 MHz) were taken in CDCl3-solution with a Jeol FX90Qspectrometer, and 13C NMRspectra were recorded as noted in Table 1 . Preparation of 5 from iV-Demethylerythromycin A iV-Demethylerythromycm A (2.0 g), obtained from erythromycin A by the method of Flynn et al.ls\ was dissolved in 30 ml of a 3 : 1 mixture of pyridine -AcOHand heated at 50°C for 14 days. The mixture was cooled, alkalinized with saturated Na2CO3solution and extracted with CH2C12. The organic layers were dried over anhydrous Na2SO4and evaporated to dryness. Crystallization from CH3CN afforded 1. 
